Leisch F, Schützenberger W, Kerschner K, Herbinger W
First Department of Internal Medicine (Cardiology), General Hospital, Linz, Austria.
Ann Med Interne (Paris). 1988;139(2):115-7.
Intravenous high-dose infusion of streptokinase in acute evolving myocardial infarction is a widely used therapeutic concept with clinically relevant recanalization rates and low complications. In our experience with 150 patients and acute myocardial infarction treated with intravenous streptokinase (1.5 Mio U), 107 (78 p. 100) of 137 patients demonstrated an antegrade perfused infarct artery. In a group of patients (n = 95), in whom early revascularization was performed, the incidence of reinfarction was reduced from 15 p. 100 to 7 p. 100; hospital mortality was not influenced (3.6 p. 100 vs 4.3 p. 100). PTCA was successful in 39 of 48 patients (81 p. 100). The incidence of angiographically determined restenosis amounted to 28 p. 100 (9/32). Patients after successful PTCA without restenosis demonstrated an improvement of left ventricular function in contrast to patients with restenosis or reocclusions. Thus, intravenous streptokinase followed by PTCA presents a clinically practicable and promising method for treatment of acute myocardial infarction.
静脉内大剂量输注链激酶治疗急性进展性心肌梗死是一种广泛应用的治疗理念，具有临床相关的再通率且并发症少。根据我们对150例接受静脉内链激酶（150万单位）治疗的急性心肌梗死患者的经验，137例患者中有107例（78%）梗死相关动脉出现前向血流灌注。在一组进行早期血运重建的患者（n = 95）中，再梗死发生率从15%降至7%；住院死亡率未受影响（3.6%对4.3%）。48例患者中有39例（81%）PTCA成功。血管造影确定的再狭窄发生率为28%（9/32）。成功进行PTCA且无再狭窄的患者与出现再狭窄或再闭塞的患者相比，左心室功能有所改善。因此，静脉内链激酶治疗后行PTCA是一种临床可行且有前景的急性心肌梗死治疗方法。
